BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1507377)

  • 1. Prescription drug diversion control and medical practice.
    Cooper JR; Czechowicz DJ; Petersen RC; Molinari SP
    JAMA; 1992 Sep; 268(10):1306-10. PubMed ID: 1507377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential.
    Simoni-Wastila L; Tompkins C
    Subst Use Misuse; 2001; 36(9-10):1275-96. PubMed ID: 11592473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PADS approach to preventing prescription drug diversion.
    Ambre JJ
    NIDA Res Monogr; 1993; 131():141-4. PubMed ID: 8413524
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription drug diversion: "what Lola wants, Lola gets".
    Thomison JB
    J Tenn Med Assoc; 1989 Jan; 82(1):35-7. PubMed ID: 2927111
    [No Abstract]   [Full Text] [Related]  

  • 5. An American Medical Association perspective on preventing prescription drug diversion.
    Ambre JJ
    NIDA Res Monogr; 1993; 131():224-7. PubMed ID: 8413533
    [No Abstract]   [Full Text] [Related]  

  • 6. Is the DEA's new "prescription series" regulation balanced?
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2008; 22(3):218-20. PubMed ID: 19042852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances.
    Joranson DE
    NIDA Res Monogr; 1993; 131():18-34. PubMed ID: 8413529
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain.
    Fishman SM; Papazian JS; Gonzalez S; Riches PS; Gilson A
    Pain Med; 2004 Sep; 5(3):309-24. PubMed ID: 15367312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug diversion control systems, medical practice, and patient care.
    Haislip GR
    NIDA Res Monogr; 1993; 131():120-31. PubMed ID: 8413522
    [No Abstract]   [Full Text] [Related]  

  • 10. The Illinois experience in achieving the medical/regulatory balance required to control prescription drug diversion.
    Bishop MT; Vlasty RJ
    NIDA Res Monogr; 1993; 131():159-75. PubMed ID: 8413527
    [No Abstract]   [Full Text] [Related]  

  • 11. Can drug design inhibit abuse?
    Coleman JJ; Bensinger PB; Gold MS; Smith DE; Bianchi RP; DuPont RL
    J Psychoactive Drugs; 2005 Dec; 37(4):343-62. PubMed ID: 16480162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEA physician registration numbers: a need to know.
    Cooper JR
    JAMA; 1994 Jan; 271(3):193-4. PubMed ID: 8277541
    [No Abstract]   [Full Text] [Related]  

  • 13. An empirical review of the impact of triplicate prescription of benzodiazepines.
    Schwartz HI
    Hosp Community Psychiatry; 1992 Apr; 43(4):382-5. PubMed ID: 1349557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Minnesota Prescription Monitoring Program.
    Herman C
    Northwest Dent; 2011; 90(2):33-5. PubMed ID: 21667591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of prescription drug diversion control systems on medical practice and patient care. Technical review, May 30-June 1, 1991. Proceedings.
    NIDA Res Monogr; 1993; 131():1-334. PubMed ID: 8413520
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescribing issues grant report to the Board of Medical Examiners. II. Minnesota Medical Association.
    Minn Med; 1990 Aug; 73(8):36-42. PubMed ID: 2398844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in opioid analgesic abuse and mortality in the United States.
    Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
    N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician perspectives on a pilot prescription monitoring program.
    Barrett K; Watson A
    J Pain Palliat Care Pharmacother; 2005; 19(3):5-13. PubMed ID: 16219606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research.
    Worley J
    Issues Ment Health Nurs; 2012 May; 33(5):319-28. PubMed ID: 22545639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.